Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Description

The purpose of this study is to evaluate the safety, efficacy, and usability of an eyedrop bottle adaptor that creates smaller eyedrops, Nanodropper, in an open-angle glaucoma/ocular hypertension patient population.

Conditions

Glaucoma, Open-Angle, Ocular Hypertension

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the safety, efficacy, and usability of an eyedrop bottle adaptor that creates smaller eyedrops, Nanodropper, in an open-angle glaucoma/ocular hypertension patient population.

Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Condition
Glaucoma, Open-Angle
Intervention / Treatment

-

Contacts and Locations

Seattle

University of Washington, Seattle, Washington, United States, 98104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥18 years old
  • * Primary open-angle glaucoma (OAG) diagnosis
  • * Ocular hypertension (OHT) diagnosis
  • * Corneal thickness \<600 µm
  • * Use 1-2 IOP-lowering eyedrop medications that are compatible with Nanodropper
  • * OAG/OHT must be well-controlled (defined as ≥2 IOP measurements collected within 6 months of recruitment that are ≤21 mm Hg with variability of ±3 mm Hg)
  • * OAG/OHT must be progression-free (as judged by the clinician and based on ≥2 stable OCT and visual field tests collected in the 6 months prior to recruitment)
  • * Uncontrolled glaucoma (IOP \>21 mmHg)
  • * Use of \>2 medications for treatment of OAG/OHT
  • * Use of eyedrop medications that are incompatible with Nanodropper
  • * OAG/OHT progression (as judged by the clinician within the past 6 months)
  • * Eye surgery including laser procedures (e.g., SLT, iridotomy) within 6 months of recruitment
  • * Diagnosis of acute angle-closure glaucoma and/or other retinal diseases

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Washington,

Raghu Mudumbai, PRINCIPAL_INVESTIGATOR, University of Washington

Study Record Dates

2025-06-30